October 20, 2017 1:51 PM ET

Biotechnology

Company Overview of Check-Points BV

Company Overview

Check-Points BV develops, produces, and commercializes products based on innovative proprietary system for routine identification of micro organisms. The company’s system enables the user to detect antimicrobial residues in food items. It offers microbial identification arrays to identify Thermofilic Bacillus Subtilis, nonThermofilic Bacillus Subtilis, and a GeoBacillus based on specific DNA markers. The company serves the industries involved in the food chain. Check-Points BV was founded in 2002 and is based in Wageningen, the Netherlands.

Agro Businesspark 90

Wageningen,  6708 PW

Netherlands

Founded in 2002

Phone:

31 317 453 908

Fax:

31 317 423 124

Key Executives for Check-Points BV

Co-Founder and Chief Executive Officer
Co-Founder and Chief Scientific Officer
Research & Development Director
Compensation as of Fiscal Year 2017.

Check-Points BV Key Developments

BD and Check-Points Announce Development and Global Distribution Agreement for BD MAX™ Assays

BD announced a development and global distribution agreement with Check-Points for BD MAX™ assays that detect carbapenem-resistant organisms (CRO). As part of the agreement, BD will distribute the Check-Direct CPE Screen for the BD MAX assay (CE IVD) outside of the United States, with Check-Points maintaining exclusivity in the Netherlands. Check-Points and BD plan to develop and commercialize a next-generation CRO assay for launch outside the U.S. in 2017 and in the U.S. at a later time. The Check-Direct CPE Screen for the BD MAX assay is a real time PCR kit for the detection of CRO from rectal swabs. The Check-Direct CPE Screen for the BD MAX identifies and differentiates the presence of the four most common carbapenemase genes: KPC, NDM, VIM and OXA-48-like (including OXA-181 and OXA-232). In three prospective European studies, the assay demonstrated overall clinical sensitivity and specificity of 98.5% and 96.8%, respectively. The Check-Direct CPE Screen for BD MAX assay is the latest offering in the BD MAX HAI portfolio, which includes IVD assays for the qualitative detection of Methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus aureus and Clostridium difficile (C. difficile). Together with other upcoming products on the BD Phoenix™ platform, BD will offer a comprehensive genotypic and phenotypic CRO solution to support clinical microbiology customers in their antimicrobial resistance programs.

Similar Private Companies By Industry

Company Name Region
ACS Biomarker B.V. Europe
Agventure Exploitatie BV Europe
Alloksys Life Sciences BV Europe
AM-Pharma B.V. Europe
Amarna Therapeutics B.V. Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Check-Points BV, please visit www.check-points.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.